1460-FinalPSD
Public Summary DocumentApplication No. 1460 – Blue-light cystoscopy with hexaminolevulinate as an adjunct to standard white light cystoscopy, for the diagnosis, treatment and management of non-muscle invasive bladder cancer (NMIBC)Applicant:Juno PharmaceuticalsDate of MSAC consideration:MSAC 72nd Meeting, 28-29 March 2018Context for decision: MSAC makes its advice in accordance with its Terms of Reference, visit the MSAC websitePurpose of application An application requesting Medicare Benefits Schedule (MBS) listing of blue-light rigid cystoscopy (BLC) with hexaminolevulinate (HAL) as an adjunct to white light rigid cystoscopy (WLC) for the diagnosis, treatment and management of non-muscle invasive bladder cancer (NMIBC) was received from Juno Pharmaceuticals by the Department of Health.BLC with HAL has been developed to better visualise tumours for diagnosis and biopsy. This is intended to enable more complete detection and resection of bladder lesions, to allow better risk stratification and improved detection of recurrence during follow-up. MSAC’s advice to the MinisterAfter considering the strength of the available evidence in relation to comparative safety, clinical effectiveness and cost-effectiveness, MSAC supported MBS funding of BLC with HAL as an adjunct to standard WLC, for the diagnosis, treatment and management of NMIBC. MSAC advised there was weak but acceptable evidence of safety, clinical effectiveness and cost-effectiveness with low financial impact. MSAC advised that the MBS fee should be reflective of the existing WLC service cost with an additional input cost of $65 for the instillation of HAL. MSAC advised it was not reasonable to include an additional input cost for catheterisation or the cost of the consumable HAL. MSAC agreed with the advice from the Department that the cost of the HAL component of this service should be met under the National Procedure Banding arrangements. MSAC advised that this MBS item should be reviewed 12 months post-implementation and requested that the Department write to the Urological Society of Australia and New Zealand (USANZ) for advice on the likely uptake of the service when listed. Summary of consideration and rationale for MSAC’s advice MSAC noted that the application sought a listing on the MBS for BLC with HAL as an adjunct to rigid WLC for the diagnosis, treatment and management of NMIBC. Cystoscopy is used to visualise the inside of the bladder and urethra to look for abnormalities or to find causes of blockage or bleeding. The standard procedure uses white light; BLC uses an optical imaging agent (HAL) which gets absorbed by cancer cells and causes them to glow pink under blue light, highlighting tumours that may not have been visible using white light alone.MSAC noted that the five-year recurrence rate for bladder cancer is high (between 31% for low risk and 78% in high risk cases), and noted that incomplete transurethral resection of bladder tumours (TURBT) is a likely contributor to this, with additional tumours found at first post-TUR surveillance in up to 45% of patients.MSAC noted the two proposed populations considered in the application:patients with suspected (new or recurrent) bladder cancer undergoing rigid cystoscopy with or without biopsy and/or resection for the purposes of diagnosis and treatment (population 1); and asymptomatic patients with previously diagnosed NMIBC, who are undergoing subsequent follow-up or surveillance with rigid cystoscopy for disease recurrence (population 2). MSAC noted that the comparator for BLC with HAL is WLC.MSAC noted that the evidence presented showed that BLC with HAL + WLC has non-inferior safety versus WLC alone (unless HAL is contraindicated). In the largest study in which comparative safety was assessed (Stenzl et al., 2010: n = 726) the proportion of patients experiencing adverse events was similar for both groups (55.3% BLC with HAL + WLC versus 53.5% WLC only, not significant).MSAC noted that the evidence base of eight randomised controlled trials (n = 1487) applied to population 1 only and that no studies addressed population 2 (surveillance of asymptomatic patients). MSAC noted that there were significant limitations in the evidence with all included studies at high or unclear risk of bias, high levels of heterogeneity and varying ranges of follow-up (six weeks to 4.5 years). MSAC noted that six studies provided evidence of reasonable diagnostic performance, all of which had high or unclear risk of bias. Evidence showed:BLC with HAL was found to have higher sensitivity than WLC alone in six studies and lower specificity in five studies (specificity was the same in one study);accuracy per lesion:improved sensitivity for BLC with HAL + WLC compared to WLC (more lesions detected; range 0.76 to 0.99 versus 0.46 to 0.88, respectively);slightly lower specificity for BLC with HAL + WLC compared to WLC (more false-positives; range 0.30 to 1.00 versus 0.37 to 1.00, respectively);accuracy per patient (two out of six studies):improved sensitivity for BLC with HAL + WLC compared to WLC (0.89 to 0.96 versus 0.73 to 0.79, respectively);similar values for specificity of the two procedures (0.43 to 1.00);wide variation in incremental accuracy of between 3 and 230 additional lesions found and between 3 and 104 true positives and 0 to 126 false positives, and that this variation was unexplained.MSAC considered that the consequences of a false positive result would be limited by histopathology but may result in more extensive resection and/or single dose intravesical chemotherapy. MSAC noted that inflammatory changes (cystitis, previous resection, previous intravesical chemotherapy or Bacille Calmette-Guerin [BCG] instillation) can contribute to false-positive BLC with HAL for 6-12 weeks: 5 of the 8 RCTs excluded patients who had received intravesical chemotherapy or BCG within 6 weeks (1 study) or 3 months (4 studies).MSAC noted that the use of BLC with HAL + WLC was reported to change the clinical management in approximately 20% of patients as a result of better detection of bladder cancer and improved risk stratification (Geavlete B et al 2012; Gkritsios P et al 2014), and considered that this should decrease recurrence rate and reduce progression to muscle invasive bladder cancer.MSAC noted that the evidence presented for comparative effectiveness showed that BLC with HAL has non-inferior safety and superior effectiveness for rate of recurrence, median time to recurrence and recurrence-free survival but uncertain effectiveness for rate of progression and progression-free survival, relative to WLC. MSAC noted:rate of recurrence was consistently lower in all studies with statistically significant reductions seen in five studies (Geavlete B et al 2010; Geavlete B et al 2012; Gkritsios P et al 2014; Hermann G et al 2011; Karaolides T et al 2012);benefit maintained at two years (two studies; Geavlete B et al 2012; Gkritsios P et al 2014);recurrence–free survival – statistically significant increase in four of five studies (Dragoescu O et al 2011; Grossman H et al 2012; Hermann G et al 2011; Karaolides T et al 2012);time to recurrence – significantly longer in two of three studies, with a median difference of four to seven months (Grossman H et al 2012; Karaolides T et al 2012);rate of progression – non-significant reduction at one year in four studies; mortality – no improvements at 4.5 years follow-up in one study, underpowered to detect outcome of interest (Grossman H et al 2012);residual tumour – increase in additional tumours detected by BLC after resection under WLC, of 8.5% and 49% (two studies; reason for divergence unclear; Geavlete B et al 2012; Hermann G et al 2011).MSAC noted the omission of a patient-level meta-analysis which demonstrated comparative effectiveness (Burger M et al 2013), with a 24.9% increase in additional Ta or T1 papillary lesions and an additional 26.7% carcinoma in situ lesions (TCIS) detected by BLC with HAL + WLC, and a reduction in recurrence rates at one year compared to WLC alone (risk ratio, 0.76, p = 0.006). MSAC also noted the lower risk of progression for the use of BLC with HAL + WLC found in the meta-analysis included in the Agency for Healthcare Research and Quality Comparative Effectiveness Review No.153 (Chou R et al 2016).MSAC considered that although there were no studies of the safety or effectiveness of BLC with HAL for follow-up surveillance of asymptomatic patients with NMIBC (population 2), it was highly likely that due to the potential overlap of surveillance and recurrence, there may be some merging of population 2 with population 1 because identifying lesions through surveillance would be of benefit to patients, given the high risk of recurrence.Based on the evidence of effectiveness, MSAC considered the economic model in which BLC with HAL + WLC is used: (i) to guide resection of NMIBC; and (ii) as part of follow-up surveillance after diagnosis, resection and treatment of NMIBC.MSAC noted that the base-case incremental cost-effectiveness ratio (ICER) was dominant (incremental cost, -$4153; incremental effectiveness, 0.12 quality adjusted life years). MSAC noted that incremental effectiveness and cost savings were maintained in a number of sensitivity analyses with the exception of risk of recurrence.MSAC noted that there were some translation issues associated with the economic model:patients with CIS only were excluded from one of the trials (Dragoescu O et al 2011);the extrapolation of recurrence- and progression-free survival beyond the study duration of 4.5 years to a lifetime time horizon; andutilities were taken from studies of overseas populations, and may not be relevant in the Australian setting but were most likely transferrable.MSAC agreed, based on the advice provided by ESC and the Department, that the MBS costs should exclude the costs of catheterisation for the instillation of HAL, preparation fees, and the cost of HAL. MSAC noted that the revised financial estimates were based on current MBS utilisation data. The revised financial estimates provided a net cost to the MBS i.e. MBS cost of BLC with HAL minus the MBS cost of WLC, which significantly reduced the costs to the MBS presented in the initial assessment (~$14 million). MSAC noted that the revised estimates of the cost of extra test positives resulting from the use of BLC with HAL and reduction of recurrence associated with the intervention generated an additional cost of between $1,870,689 and $5,333,038. However, MSAC considered that this could be an overestimation, as:the utilisation data assumed that all cystoscopy items are claimed for bladder cancer, which was unlikely; and 100% uptake of BLC with HAL was assumed; this had not been demonstrated in Scandinavia where uptake after five years was 27%.MSAC considered that the costs and feasibility of upgrading current systems to BLC with HAL, estimated at ~$35,000 to $85,000, might also slow the uptake of the procedure, and that there were additional minor considerations around the degree of training required and associated cost which had not been addressed. MSAC discussed the impact of low uptake of the service on the availability to consumers, and considered that communications to consumers should address access limitations due to the numbers of providers performing the service.MSAC considered the advice provided by the Department that as HAL is a consumable it was inappropriate to be included as a component of the MBS fee, and agreed that the cost of HAL would be better accommodated under National Procedure Banding arrangements. MSAC considered that advice should be sought as to the level at which banding will apply, as there had been a decline in the cost of HAL overseas. MSAC advised that the MBS fee should be reflective of the existing WLC service cost with an additional input cost of $65 for the instillation of HAL. MSAC advised it was not reasonable to include an additional input cost for catheterisation as it is a routine part of the procedure and is currently very rarely co-claimed with cystoscopy items. MSAC considered the applicant’s claim that BLC with HAL + WLC is an internationally recognised standard of care, noting that this was not the case in either Europe or the United States (Babjuk M et al 2017; Chang SS et al 2016).MSAC advised that the decision was to accept listing of the item on the MBS based on evidence that BLC with HAL + WLC appears to be safe, clinically effective and cost-effective, and that the financial impact would be low. MSAC recommended supporting listing for both proposed populations, as identifying lesions through surveillance would be of benefit to patients given the high risk of recurrence. MSAC advised that this MBS item should be reviewed 12 months following listing and requested that the Department write to the Urological Society of Australia and New Zealand (USANZ) for advice on the likely uptake of the service when listed.BackgroundMSAC has not previously considered this application.Prerequisites to implementation of any funding adviceOnly TGA registered cystoscopic equipment should be used, equipped with necessary filters to allow both standard white light cystoscopy and blue light (wavelength 380-450 nm) fluorescence cystoscopy. HAL is TGA registered for diagnostic use only.BLC with HAL must be performed by healthcare professionals trained in cystoscopy (e.g. urologists) and also with experience in blue light imaging as an adjunct to white light imaging. Training options are peer-to-peer interaction and onsite training, the equipment manufacturers and HAL sponsor also offer training options.Proposal for public fundingThe proposed MBS item descriptors are summarised in REF _Ref508113742 \h \* MERGEFORMAT Table 1.Table SEQ Table \* ARABIC 1Proposed MBS item descriptorsCategory: – New item number - Investigative cystoscopic item using blue light with hexaminolevulinate as an adjunct to white light for conduct of biopsyRIGID CYSTOSCOPY using blue light with hexaminolevulinate as an adjunct to white light, including catheterisation, with biopsy of bladder, not being a service associated with a service to which item 36812, 36830, 36840, 36845, 36848, 36854, 37203, 37206 or 37215 applies (anaesthesia).Fee: $229.85 Benefit :75% = $172.40 85% = $195.40Category: – New item number - Therapeutic cystoscopic item using blue light with hexaminolevulinate as an adjunct to white light with concurrent resection of tumourRIGID CYSTOSCOPY using blue light with hexaminolevulinate as an adjunct to white light, including catheterisation, with resection, diathermy or visual laser destruction of bladder tumour or other lesion of the bladder, not being a service to which item 36845 applies (anaesthesia).Fee: $323.20 Benefit :75% = $242.40 85% = $274.75Category – New item number - Therapeutic cystoscopic item using blue light with hexaminolevulinate as an adjunct to white light with concurrent resection of tumourRIGID CYSTOSCOPY using blue light with hexaminolevulinate as an adjunct to white light, including catheterisation, with diathermy, resection or visual laser destruction of multiple tumours in more than 2 quadrants of the bladder or solitary tumour greater than 2cm in diameter (anaesthesia).Fee: $691.40 Benefit :75% = $172.40 85% = $195.40Category: – New item number - Investigative cystoscopic item using blue light with hexaminolevulinate as an adjunct to white light for routine scheduled (follow-up) managementRIGID CYSTOSCOPY using blue light with hexaminolevulinate as an adjunct to white light, including catheterisation, with urethroscopy with or without urethral dilatation, not being a service associated with any other urological endoscopic procedure on the lower urinary tract except a service to which item 37327 applies (anaesthesia).Fee: $166.70 Benefit :75% = $125.05 85% = $141.70Summary of Public Consultation Feedback/Consumer IssuesOne response was received from an organisation to the targeted consultation survey. The response noted that the proposed service will provide a more accurate identification of small lesions within the bladder at cystoscopy, which may potentially be missed on white light cystoscopy. Better identification assists pathological classification, potentially reducing recurrences of tumours and allowing appropriate and timely intravesical therapies and treatment of carcinoma in situ.Proposed intervention’s place in clinical managementThere are two proposed patient populations:Population 1: Patients with suspected bladder cancer who are undergoing rigid cystoscopy with or without biopsy and/or resection.These patients are those in whom there is a clinical suspicion of bladder cancer, or previous testing (urine cytology and, in some patients, imaging and/or flexible cystoscopy) has raised the suspicion of bladder cancer. They are undergoing rigid cystoscopy during which they may have a biopsy or a resection.Population 2: Asymptomatic patients with previously diagnosed NMIBC (proven by biopsy or resection), who are undergoing subsequent follow-up or surveillance for disease recurrence with rigid cystoscopy.BLC with HAL is proposed to be used as an adjunct to WLC, therefore it is used whenever WLC is recommended in the clinical management algorithm.Figure SEQ Figure \* ARABIC 1Clinical management algorithm for BLC with HAL relative to current management Comparator The comparator is standard WLC, which is currently used in the Australian health care system.The reference standard used to determine the accuracy of BLC with HAL compared to WLC is parative safetySimilar proportions of patients experienced adverse events in one comparative study (55.3% in the BLC group vs 53.5% in the WLC group). Serious adverse events were also similar in both groups (10.7% vs 8.9% of patients). Adverse events related to HAL instillation occurred in 1.0% to 2.6% of patients with haematuria being the most common.BLC with HAL appears to have non-inferior safety to WLC parative effectivenessRate of recurrenceEight studies found that recurrence rates were lower in the BLC with HAL group than the WLC only group at all follow-up times (except at 3 months in one study).One applicable study found recurrence rates of 7.2% in the BLC with HAL group compared to 15.8% in the WLC at 3 months (RR=0.46; 95%CI: 0.21, 0.97), 21.6% versus 32.5% at 12?months (RR=0.67; 95%CI: 0.43, 1.02) and 31.2% versus 45.6% at 24 months (RR=0.68; 95%CI: 0.49, 0.95).Another applicable study reported that the RR of recurrence was 0.84 (95%CI: 0.72, 0.99) at 3 months and 0.91 (95%CI: 0.80, 1.03) at 24 months.Recurrence-free survivalFour of the five studies that reported recurrence-free survival found a statistically significant increase in recurrence-free survival in the BLC with HAL group compared to the WLC group. Time to recurrenceThree studies found a longer median time to recurrence; in two this difference was statistically significant. The difference in median time to recurrence ranged from 4 to 7 months.Rate of progressionFour studies reported on the rate of progression and all found a non-statistically significant reduction in the progression rates in the BLC with HAL group compared to the WLC group at one year.One highly applicable study found progression rates of 2.4% and 4.4% in the BLC with HAL group and WLC group respectively (RR=0.55; 95%CI: 0.13, 2.24) at one year and 4.0% versus 7.0% T 2 years (RR= 0.57; 95%CI: 0.19, 1.69).Progression-free survivalOne study found that progression-free survival was marginally significantly improved with BLC with HAL (p=0.05).MortalityOne study found that mortality was not significantly different between the BLC with HAL and WLC groups up to 4.5 years, but was considered to be underpowered for this outcome.Residual tumourBLC with HAL detected residual tumour in 49% of patients in one study and 8.5% of patients in another. On the basis of the included evidence, it is suggested that, relative to the comparator, the intervention has non-inferior safety and superior effectiveness for rate of recurrence, median time to recurrence and recurrence-free survival. Moreover, it is suggested that the intervention has uncertain effectiveness for rate of progression and progression-free survival. No conclusion can be made about mortality due to the studies not being powered to detect this outcome. There is evidence from two studies that BLC with HAL is likely to result in less residual tumour after TURBT; however the true magnitude of this is uncertain.Effectiveness from linked evidenceAccuracyEvidence for the comparative and incremental accuracy of BLC with HAL as an adjunct to WLC relative to WLC alone comes from two level III-2 studies and four level III-3 studies.On the basis of this evidence, it is proposed that BLC with HAL as an adjunct to WLC is more sensitive on a per-lesion basis in detecting bladder cancer than WLC alone but less specific. On a per person basis the evidence is less robust but does suggest that BLC with HAL is more sensitive than WLC. There is no change in the specificity on a per-patient basis when WLC with HAL is added to WLC. With regards to incremental accuracy, the evidence suggests that BLC with HAL will detect more cancers and this will result in more biopsies or resection of healthy parative accuracyBLC with HAL was found to have a higher sensitivity than WLC alone in six studies and a lower specificity in five studies (specificity was the same in one study).The most applicable study found the sensitivity of BLC with HAL was 0.93 (95%CI: 0.91, 0.95) compared to 0.76 (95%CI: 0.73, 0.80) in WLC and specificity was 0.74 (95%CI: 0.71, 0.77) and 0.87 (95%CI: 0.85, 0.89) respectively. Two studies show that BLC with HAL is more sensitive to detecting bladder cancer per person but just as specific as WLC alone: the most reliable and applicable study reported sensitivity to be 0.96 (95%CI: 0.85, 0.99) for BLC with HAL versus 0.73 (95%CI: 0.58, 0.85) for WLC; specificity was 0.43 (95%CI: 0.10, 0.82) for both BLC and WLC.Incremental accuracyThe incremental accuracy was highly variable with between 3 and 230 additional lesions detected by BLC with HAL with between 3 and 104 true positives and 0 to 126 false positives.The most applicable study with the largest sample size found that for every additional true positive there was approximately another false positive detected.Therapeutic efficacy and effectiveness (change in management and health benefit from change in management)Based on the evidence provided in the Contracted Assessment Report, the use of BLC with HAL as an adjunct to WLC will change the clinical management in approximately 20% of patients. This is due to categorising patients in a higher risk group which results in their receiving more appropriate treatment which, it is suggested, improves clinical outcomes.Clinical ClaimIt is proposed that BLC with HAL has non-inferior safety and superior effectiveness and diagnostic accuracy to WLC. It is proposed that BLC with HAL as an adjunct to WLC will result in improved detection and more complete resection of bladder lesions leading to more accurate risk stratification and thus more appropriate treatment and management post-operatively. This, in turn, may lead to reduced rates of recurrence, longer times to recurrence, reduced rates of progression and longer times to progression to muscle invasive disease. In addition, surgery may be avoided due to more accurate diagnosis and more complete resection. Moreover, there may be improved progression-free survival and overall survival due to more appropriate entry into the clinical management pathway (e.g. earlier if diagnosis is more accurate) and more appropriate management (e.g. more appropriate treatment regimens due to better risk stratification).Economic evaluationA cost utility analysis was undertaken for the economic evaluation of BLC with HAL as an adjunct to WLC for population 1 - patients with suspected bladder cancer who are undergoing rigid cystoscopy with or without biopsy and/or resection. A summary of the economic evaluation is shown in REF _Ref508113828 \h Table 2.Table SEQ Table \* ARABIC 2Summary of the economic evaluationPopulationPatients where there is a clinical suspicion of bladder cancer, or previous testing – cytology and, in some patients, imaging and/or flexible cystoscopy – has raised the suspicion of bladder cancerPerspectiveAustralian governmentComparatorStandard white light cystoscopyType of economic evaluationCost utility analysisPrimary sources of evidencePEVuZE5vdGU+PENpdGUgQXV0aG9yWWVhcj0iMSI+PEF1dGhvcj5QYWxvdTwvQXV0aG9yPjxZZWFy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ADDIN EN.CITE PEVuZE5vdGU+PENpdGUgQXV0aG9yWWVhcj0iMSI+PEF1dGhvcj5QYWxvdTwvQXV0aG9yPjxZZWFy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ADDIN EN.CITE.DATA Palou et al. (2015), PEVuZE5vdGU+PENpdGUgQXV0aG9yWWVhcj0iMSI+PEF1dGhvcj5Hcm9zc21hbjwvQXV0aG9yPjxZ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ADDIN EN.CITE PEVuZE5vdGU+PENpdGUgQXV0aG9yWWVhcj0iMSI+PEF1dGhvcj5Hcm9zc21hbjwvQXV0aG9yPjxZ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ADDIN EN.CITE.DATA Grossman et al. (2012), PEVuZE5vdGU+PENpdGUgQXV0aG9yWWVhcj0iMSI+PEF1dGhvcj5Nb3dhdHQ8L0F1dGhvcj48WWVh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ADDIN EN.CITE PEVuZE5vdGU+PENpdGUgQXV0aG9yWWVhcj0iMSI+PEF1dGhvcj5Nb3dhdHQ8L0F1dGhvcj48WWVh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ADDIN EN.CITE.DATA Mowatt et al. (2010)Time horizonLife timeOutcomesQuality Adjusted Life Years (QALYs)Methods used to generate resultsDecision tree followed by Markov cohort modelHealth statesNon-muscle invasive (low risk); Non-muscle invasive (intermediate risk); Non-muscle invasive (high risk); Non-muscle invasive recurrence (low risk); Non-muscle invasive recurrence (intermediate risk); Non-muscle invasive recurrence (high risk); No tumour recurrence (non-muscle invasive - low risk) – surveillance; No tumour recurrence (non-muscle invasive - intermediate risk) – surveillance; No tumour recurrence (non-muscle invasive - high risk) – surveillance; Muscle invasive; No tumour recurrence (muscle invasive); Non metastatic muscle invasive recurrence; Metastatic muscle invasive recurrence; Tumour related death; Natural deathCycle length3 monthsDiscount rate5%Software packages usedTreeAge Pro? 2017 R2.0The overall costs and outcomes, and incremental costs and outcomes as calculated for the test and comparator in the model, and with the base case assumptions, are shown in REF _Ref508113877 \h Table 3.Table SEQ Table \* ARABIC 3Base case incremental costs effectiveness ratioBASE CASECostIncremental costEffectiveness (QALYs)Incremental effectivenessBLC+WLC$63,536($4,153)7.290.12WLC$67,6897.17Abbreviations: ICER = Incremental Cost Effectiveness Ratio; QALY = quality adjusted life year; WLC = white-light cystoscopy; BLC = blue-light cystoscopy.The sensitivity analysis found that when diagnostic accuracy values, male/female gender, disease severity at diagnosis and age at diagnosis are modified, BLC with HAL remains dominant. The economic model was sensitive to variations in the relative risk of recurrence of BLC with HAL as an adjunct to WLC compared to WLC alone. Financial/budgetary impactsAn epidemiological approach was used to estimate the financial implications of the introduction of BLC with HAL as an adjunct to WLC.The financial implications to the MBS resulting from the proposed listing of BLC with HAL as an adjunct to WLC are summarised in REF _Ref508113910 \h Table 4.Table SEQ Table \* ARABIC 4Total costs to the MBS associated with BLC with HAL as an adjunct to WLCPopulation20182019202020212022Annual cost, initial BLC with HAL in patients with suspected bladder cancer$8,332,820$8,455,859$8,563,518$8,677,330$8,792,679Total annual cost, 1st year after presentation, all patients$26,485,522$26,875,706$27,215,474$27,578,912$27,948,268Annual cost all NMIBC, 1st year surveillance$6,885,203.$7,040,506.$7,198,105 $7,355,579 $7,512,326Total annual cost, incident and prevalent cases$ 33,370,726$33,916,212$34,413,580$34,934,493$35,460,595The cost of BLC using the weighted average of the MBS items based on 2016 utilisation, adding the cost of HAL, catheterisation item cost, and preparation cost is $1,390.51 per patient.Updated financial costs were provided by the assessment group using the average costs per person of BLC and WLC and taking a market-based approach as recommended in the Critique and by the Applicant. Based on these estimates the net cost to the MBS could be an additional cost of between $1,870,689 and $5,333,038 assuming a 100% uptake of the BLC technology (Table 5). There is considerable uncertainty in these figures which may, in fact, include a cost neutral result.Table 5 MBS costs adjusted for extra positive tests and reduction of recurrence associated with BLC with HAL as an adjunct to WLC?AssumptionCost to MBSDistribution of extra test results same as utilisation distribution$5,333,038.35All of the extra positive tests involve biopsy only$1,870,689.66Using uptake rates supplied by the Applicant of the Scandinavian experience, the associated additional costs for each year after introduction are estimated in Table 6.Table 6 Additional cost estimates based on uptake data supplied by the ApplicantYear 12345% uptake2%8%13%21%27%Additional cost*$106,660.77$426,643.07$693,294.99$1,119,938.05$1,439,920.35Additional cost?$37,413.79$149,655.17$243,189.66$392,844.83$505,086.21* assuming the extra positive tests are distributed as per the utilisation cohort from July 2016 to June 2017? assuming that the extra positive tests involve biopsy onlyKey issues from ESC for MSACThis submission is a new application to support the listing on the Medicare Benefits Schedule (MBS) of blue light cystoscopy (BLC) with hexaminolevulinate (HAL). This service would be used as an adjunct to rigid white light cystoscopy (WLC) for the diagnosis, treatment and management of non-muscle invasive bladder cancer (NMIBC).ESC noted that there are two proposed populations considered in this application. The populations are:patients with suspected (new or recurrent) bladder cancer undergoing rigid cystoscopy with or without biopsy and/or resection for the purposes of diagnosis and treatment (population 1); and asymptomatic patients with previously diagnosed NMIBC, who are undergoing subsequent follow-up or surveillance with rigid cystoscopy for disease recurrence (population 2). ESC noted the pre-test probability of disease is higher in this population.ESC queried the inclusion of both suspected new and suspected recurrent cases in population 1, but noted that only one study was restricted to suspected new NMIBC cases (O’Brien T et al 2013); the remaining studies were mixed or unspecified populations.ESC noted that the current joint guidelines of the American Urological Association and the Society of Urologic Oncology (Chang S et al 2016) recommend the use of BLC with HAL (BLC with HAL) for routine surveillance of NMIBC following transurethral resection of the bladder. The European Association of Urology guidelines (Babjuk M et al 2017) recommended its use (i) after intravesical treatment (at 3 or 6 months) in patients with carcinoma in situ (CIS, Grade C recommendation); and (ii) in patients with positive cytology and no visible tumour in the bladder (Grade B recommendation) – such patients (with positive cytology) are not considered truly “asymptomatic”.ESC noted that there were no studies of the safety or effectiveness of BLC with HAL for follow-up surveillance of asymptomatic patients with NMIBC (population 2), the population in which high utilisation would be expected.ESC noted that there were significant limitations in the evidence base with all included studies at high or unclear risk of bias, with high levels of heterogeneity. ESC noted that BLC with HAL + WLC has non-inferior safety versus WLC alone (unless HAL is contraindicated). In the most comprehensive study (Stenzl et al. 2010), the proportion of patients experiencing adverse events was similar for both groups (55.3% BLC with HAL + WLC versus 53.5% WLC only).ESC noted that the populations included in the diagnostic accuracy trials were not homogenous; some studies included only patients with suspected NMIBC (initial cancer only) and/or recurrence; other studies included routine follow-up patients.ESC noted that six studies provided evidence of diagnostic performance, all of which had high or unclear risk of bias. Evidence showed:BLC with HAL had higher sensitivity than WLC alone in six studies and lower specificity in five studies (specificity was the same in one study);accuracy per lesion:improved sensitivity for BLC with HAL + WLC compared to WLC (more lesions detected: range 0.76 to 0.99 versus 0.46 to 0.88, respectively);slightly lower specificity for BLC with HAL + WLC compared to WLC (more false-positives: range 0.30 to 1.00 versus 0.37 to 1.00, respectively);accuracy per patient (two out of six studies):improved sensitivity for BLC with HAL + WLC compared to WLC (0.89 to 0.96 versus 0.73 to 0.79, respectively);similar values for specificity of the two procedures (0.43 to 1.00);wide variation in incremental accuracy of between 3 and 230 additional lesions found and between 3 and 104 true positives and 0 to 126 false positives, and that this variation that was unexplained.ESC noted that the use of BLC with HAL as an adjunct to WLC was reported to change the clinical management in approximately 20% of patients. This information was derived from two of the RCTs that demonstrated a statistically significant reduction in recurrence (Geavlete B et al 2012; Gkritsios P et al 2014).ESC noted that relative to the comparator, BLC with HAL has non-inferior safety and superior effectiveness for rate of recurrence, median time to recurrence and recurrence-free survival but uncertain effectiveness for rate of progression and progression-free survival. ESC noted that of eight studies providing evidence for comparative effectiveness for BLC with HAL compared to the comparator:rate of recurrence was consistently lower in all studies with statistically significant reductions seen in five studies (Geavlete B et al 2010; Geavlete B et al 2012; Gkritsios P et al 2014; Hermann G et al 2011; Karaolides T et al 2012);benefit maintained at two years (two studies; Geavlete B et al 2012; Gkritsios P et al 2014);recurrence–free survival – statistically significant increase in four of five studies (Dragoescu O et al 2011; Grossman H et al 2012; Hermann G et al 2011; Karaolides T et al 2012);time to recurrence – significantly longer in two of three studies, with a median difference of four to seven months (Grossman H et al 2012; Karaolides T et al 2012);rate of progression – non-significant reduction at one year in four studies; mortality – no improvements at 4.5 years follow-up in one study, underpowered to detect outcome of interest (Grossman H et al 2012);residual tumour – increase in additional tumours detected by BLC after resection under WLC, of 8.5% and 49% (two studies; reason for divergence unclear; Geavlete B et al 2012; Hermann G et al 2011).ESC noted the omission of a patient-level meta-analysis which demonstrated comparative effectiveness (Burger M et al 2013), with a 24.9% increase in additional papillary lesions and an additional 26.7% CIS lesions detected by BLC with HAL + WLC, and a reduction in recurrence rates at one year compared to WLC alone. ESC also noted that in contrast to the results presented in the assessment, the use of BLC with HAL in conjunction with WLC was associated with a lower risk of progression in a meta-analysis included in the Agency for Healthcare Research and Quality Comparative Effectiveness Review No.153 (Chou R et al 2016).ESC noted that the economic model had undergone extensive revision, including the addition of HAL as a resource cost, following feedback by the critique that had identified differences between the model and the literature, and had queried the ability of the model to assess the cost-effectiveness of BLC with HAL versus WLC. ESC noted that the base-case incremental cost-effectiveness ratio (ICER) was dominant over WLC alone. ESC noted that sensitivity analyses showed that the intervention was dominant for all other inputs with the exception of risk of recurrence. ON the other hand, the incremental cost and QALY components of the ICERs were not provided, and ESC considered that the reporting of the incremental cost and incremental benefit components of the ICER is necessary in order to determine whether costs or outcomes are the main drivers of the ICER.ESC noted the variable lengths of follow-up in the included studies, which ranged from 6 weeks to 4.5 years. ESC considered that the extrapolation of recurrence- and progression-free survival beyond the study duration of 4.5 years was a key translation issue for the economic model. ESC noted that the risk of recurrence extrapolated to a 20 year time line is the same regardless of whether a patient has a low, intermediate or high risk NMIBC. ESC also considered that the application of utilities and probabilities for recurrence, progression and mortality included in the model presented a translation issue, as no discussion had been provided as to the source of the utilities or the relevance to an Australian population. In the source of the utilities, patients with NMIBC, confirmed by histopathology, are assumed to be at low, intermediate or high risk of progression, but no discussion is provided as to the applicability of these risk allocations to Australian clinical practice. ESC also noted that patients with CIS only were excluded from one of the trials (Dragoescu O et al 2011), and that this may present a minor translation issue in terms of the applicability of the data in the model, since patients with CIS account for only 2.9% of all presentations of NMIBC.ESC noted that the applicant had highlighted an omission in the clinical algorithm, whereby for a substantial proportion of low-risk patients for whom there is no clinical suspicion of recurrence, follow-up may be in the outpatient setting using flexible cystoscopy. ESC agreed that this was not proposed in the agreed PICO presented to PASC, and should not be included in the model.ESC noted that despite the revisions to the model, and the consequent dominance of the intervention in the sensitivity analyses performed regarding accuracy and comparative effectiveness inputs, the financial estimates had not been revised. ESC noted that the financial implications are considerable when the cost of HAL is included in the MBS fee, rising from approximately $14 million to between $33.37 million and $35.46 million over five years, based on the usage estimates provided.Aside from the exclusion of the cost of HAL, ESC noted there were several additional factors requiring consideration that had been omitted from the financial estimates in the contracted assessment, being:additional costs and feasibility issues with upgrading current systems to enable the procedure to be performed; associated costs and needs of training for the procedure to be undertaken;the impact of the procedure on operating theatre workflows; andpossible restrictions on use to minimise the false positive rate associated with the procedure (e.g., exclusion of patients within 6-12 weeks of intravesical chemotherapy or Bacille Calmette-Guerin [BCG]).ESC noted that these factors would result in the considerable underestimation of health system costs associated with the use of BLC with HAL. ESC noted that in light of this, the financial estimates in the contracted assessment should be redone.ESC also queried the appropriateness of the fee structure, given that WLC will always be used in conjunction with the procedure and should be costed as such (BLC with HAL as an adjunct to WLC).ESC noted that the applicant has proposed the MBS item codes should reflect the existing cost structure for the WLC item, plus the addition of costs for initial catheterisation for instillation of visualisation agent (based on MBS item 36800; fee $27.60), plus the cost of instillation of the visualisation agent (based on MBS item 13948; fee $62.25), plus the cost of HAL ($775), resulting in a fee for the intervention in the range of $1031.58 to $1556.28. ESC queried the inclusion of the cost of $62.25 for instillation of the visualisation agent and queried whether this claim was valid as this process is an integral part of the overall procedure. ESC queried the proposed unit cost of HAL ($775), noting that this is the commercial cost (price to the wholesaler) and no information had been provided as to how this cost is derived. ESC discussed the cost and reimbursement of HAL, noting that HAL does not meet the criteria for listing on either the Pharmaceutical Benefits Scheme (PBS) or the Prostheses List, and that HAL should not be a component of the MBS (as it is a consumable). ESC also considered that the inclusion of HAL in an MBS fee may have the effect of setting a floor price. ESC noted advice from the Department of Health that as BLC with HAL is an in-hospital procedure, funding may be possible under the National Procedure Banding (NPB) arrangements ESC noted that under the NPB arrangements, WLC services are categorised as Band 1 (MBS item 36812) and Band 2 (MBS items 36836 and 36840). ESC noted that as the direct cost range for these bands is not high enough to include the cost of HAL, the new BLC with HAL items would need to be allocated higher theatre bands appropriate to cover the additional cost of HAL ESC noted that under this arrangement the theatre costs for BLC with HAL would have a higher benefit than the comparator WLC procedure and the additional payment could provide cost coverage of HAL.ESC considered that new technologies such as narrow-band imaging may have an impact on the uptake of this service and future use, but that no data were available.ESC noted that as false positives can occur (due to high-grade dysplasia [a premalignant condition], or inflammation from prior transurethral resection of bladder lesions, intravesical BCG, intravesical chemotherapy or infection), restrictions to the item descriptor should be considered to minimise the rate of false positives. However, ESC noted that the consequences of a false positive result, revealed by histopathology, were likely to be limited to more extensive resection and/or a single dose of intravesical chemotherapy.ESC considered that given this intervention is requested for two populations (diagnosis and treatment), it may have been more appropriate to present separate clinical management algorithms for the different target populations, as suggested in the critique.ESC noted that the algorithm does not account for contraindications for the use of HAL. ESC noted that the method of reimbursement of HAL may have an impact on equity for patients if HAL is an out-of-pocket expense. Additional equity issues for consumers include access barriers to services due to the requirement for upgraded procedures, especially for rural/remote or uninsured patients or those with no access to private sector services.ESC Key ISSUESESC ADVICEItem descriptorQuery restrictions to reduce FP rateProposed feeESC queried the inclusion of the cost of $62.25 for instillation of the visualisation agent and the proposed unit cost of HAL ($775).HAL does not meet the criteria for listing on either the Pharmaceutical Benefits Scheme (PBS) or the Prosthesis List, and that HAL should not be a component of the MBS (as it is a consumable). ESC noted that BLC with HAL is an in-hospital procedure, funding may be possible under the National Procedure Banding (NPB) arrangements Reimbursement for HALmay have an impact on equity for patients if HAL is an out-of-pocket expense‘Hidden’ costsUpgrading systems for BLCTraining in BLCImpact on OT workflowPopulationQuery 2 populations: suspected NEW bladder cancer, suspected RECURRENT bladder cancer; however, only 1 study (O’Brien et al, 2013) was restricted to suspected NEW NMIBCNo evidence of effectiveness of BLC for surveillance of asymptomatic patients (population 2)Deviance from PICOQuery model use of flexible cystoscopy for surveillance of low-risk patients – not proposed in agreed PICOEconomic evaluationQuery appropriateness of economic modelRole of new technologiesFalse positivesSensitivity analysesOther significant factorsNilApplicant’s comments on MSAC’s Public Summary DocumentJuno Pharmaceuticals welcomes MSAC’s decision to support the funding of Blue Light Cystoscopy (BLC) with hexaminolevulinate (HAL) as an adjunct to standard White Light Cystoscopy (WLC), for the diagnosis, treatment and management of NMIBC. However, Juno is concerned over the lack of clarity on the path for public reimbursement of the hexaminolevulinate. The recommendation has been made to pursue reimbursement of HAL via the National Procedure Banding arrangements which we will do. Further information on MSACMSAC Terms of Reference and other information are available on the MSAC Website: visit the MSAC website ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- 1460 finalpsd
- national pbm monograph template rev20091005
- radical cystectomy and bladder sparing treatments for
- section a applicant information
- bladder cancer clinicopathological features and
- the complete cancer survival guide 1998
- university of colorado denver
- department of health welcome to the department of health
- the burden of disease and injury in australia provides a
- siu 2020 abstract listing best eposter